enGene Therapeutics Inc. Accounts Payable
enGene Therapeutics Inc. (ENGN) had Accounts Payable of $2.54 million as of 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-09-08
- 2026-07-31: Accounts Payable, Current $2.54M.
- 2026-04-30: Accounts Payable, Current $1.79M.
- 2026-01-31: Accounts Payable, Current $2.44M.
- 2025-10-31: Accounts Payable, Current $6.69M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-07-31 | $2.54M 10-Q · filed 2026-09-08 |
| 2026-04-30 | $1.79M 10-Q · filed 2026-06-15 |
| 2026-01-31 | $2.44M 10-Q · filed 2026-03-09 |
| 2025-10-31 | $6.69M 10-Q · filed 2026-09-08 |
| 2025-07-31 | $2.38M 10-Q · filed 2025-09-11 |
| 2025-04-30 | $1.57M 10-Q · filed 2025-06-12 |
| 2025-01-31 | $2.60M 10-Q · filed 2025-03-10 |
| 2024-10-31 | $1.41M 10-K · filed 2025-12-22 |
| 2024-07-31 | $2.86M 10-Q · filed 2024-09-10 |
| 2024-04-30 | $211.00K 10-Q · filed 2024-06-14 |
| 2024-01-31 | $1.27M 10-Q · filed 2024-03-11 |
| 2023-10-31 | $1.16M 10-K · filed 2024-12-19 |
| 2022-10-31 | $723.00K 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |